Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

AZD-2563 AstraZeneca.

Alan P Johnson¹

¹Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, London, UK. ajohnson@phls.org.uk

Current Opinion in Investigational Drugs (London, England : 2000)

|July 26, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Two Decades of BSAC Resistance Surveillance.

The Journal of antimicrobial chemotherapy·2025

Same author

Epidemiology of carbapenemase-producing Enterobacterales in England, May 2015-March 2019: national enhanced surveillance findings and approach.

Infection prevention in practice·2021

Same author

Investigation of the impact of the NICE guidelines regarding antibiotic prophylaxis during invasive dental procedures on the incidence of infective endocarditis in England: an electronic health records study.

BMC medicine·2020

Same author

'Caveat emptor': the cautionary tale of endocarditis and the potential pitfalls of clinical coding data-an electronic health records study.

BMC medicine·2019

Same author

Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2019

Same author

Using hospital network-based surveillance for antimicrobial resistance as a more robust alternative to self-reporting.

PloS one·2019

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

AstraZeneca is developing AZD-2563, a novel oxazolidinone, to treat gram-positive bacterial infections, including drug-resistant strains. Phase I trials are complete, with potential launch anticipated after 2004.

Area of Science:

Pharmacology
Infectious Diseases
Drug Development

Background:

Gram-positive bacterial infections pose a significant health threat, particularly multidrug-resistant strains.
Oxazolidinones represent a class of antibiotics with a novel mechanism of action against these pathogens.

Purpose of the Study:

To summarize the development status of AZD-2563, an investigational oxazolidinone antibiotic.
To highlight its potential application in treating challenging bacterial infections.

Main Methods:

Review of development milestones and clinical trial status.
Analysis of market projections and anticipated launch timelines.

Main Results:

AZD-2563, an oxazolidinone, is under development by AstraZeneca.

Related Experiment Videos

Phase I trials in the UK were completed by December 2001, with US development ongoing.

Projected launch was anticipated after 2004, with initial sales estimates for 2004.

Conclusions:

AZD-2563 shows promise for treating gram-positive bacterial infections, including multidrug-resistant strains.
Further development and clinical trials are necessary to establish its efficacy and safety profile.